Irritable Bowel Syndrome (IBS) Treatment Market Report 2026

The irritable bowel syndrome (ibs) treatment market size has grown strongly in recent years. It will grow from $7.41 billion in 2025 to $7.97 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising prevalence of gastrointestinal disorders, increased diagnosis rates of ibs, growing awareness of digestive health, availability of prescription ibs drugs, expansion of hospital and retail pharmacy networks.

The irritable bowel syndrome (ibs) treatment market size is expected to see strong growth in the next few years. It will grow to $10.65 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advancement in precision medicine, increasing adoption of digital health platforms, growth in online pharmacy channels, rising focus on microbiome research, increasing healthcare expenditure on chronic conditions. Major trends in the forecast period include precision medicine and microbiome-based therapies, digital therapeutics and mobile health integration, AI-driven ibs diagnosis and treatment optimization, remote patient monitoring and smart gut health devices, sustainable and patient-centric drug development.

The increasing prevalence of IBS is expected to drive the growth of the IBS treatment market in the coming years. Irritable bowel syndrome (IBS) is a chronic gastrointestinal condition affecting the large intestine, leading to symptoms such as constipation, diarrhea, abdominal pain, and bloating, which can significantly affect quality of life. The rise in IBS cases is attributed to lifestyle factors, including poor diet, stress, and environmental exposures, which result in more individuals developing the disorder. The IBS treatment market addresses patient needs by offering both pharmacological therapies, such as antispasmodics and gut-targeted medications, as well as non-pharmacological interventions, including cognitive behavioral therapy, hypnotherapy, and dietary management. For example, in December 2023, the IBD Registry, a UK-based non-profit organization, reported reaching over 5,300 individuals with Inflammatory Bowel Disease (IBD) by 2023, marking an increase of more than 3,000 members compared to 2022. Therefore, the rising prevalence of IBS is fueling the growth of the IBS treatment market.

Major companies operating in the irritable bowel syndrome (IBS) treatment market are emphasizing the adoption of digital therapeutics, such as gut-directed hypnotherapy-based mobile applications, to improve patient engagement, treatment accessibility, and symptom management. Gut-directed hypnotherapy-based mobile applications are prescription digital platforms that provide structured hypnotherapy sessions through a smartphone interface to influence gut-brain interactions, offering features such as guided behavioral therapy, real-time symptom tracking, and automated monitoring of patient progress. For example, in May 2023, Launchit DTx, a Canada-based digital health commercialization company, introduced Regulora, a gut-directed hypnotherapy-based digital therapeutic developed to assist adults in managing abdominal pain associated with irritable bowel syndrome (IBS). It includes evidence-based hypnotherapy modules, clinician-enabled prescribing workflows, and a mobile app that tracks patient response over time. Regulora enhances treatment access, self-management, and overall symptom relief for IBS patients by providing a non-pharmacologic, digitally delivered therapeutic option.

In October 2023, Roche, a Switzerland-based healthcare company, acquired Telavant Holdings for an undisclosed amount. Through this acquisition, Roche will gain the rights to develop, manufacture, and commercialize a novel treatment for Irritable Bowel Syndrome (IBS) in the United States and Japan. Telavant Holdings is a US-based biotechnology company specializing in the development and commercialization of innovative therapies for inflammatory and fibrotic diseases.

Major companies operating in the irritable bowel syndrome (ibs) treatment market are Ironwood Pharmaceuticals Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson Services Inc., AstraZeneca plc, Novartis AG, Abbott Laboratories, Eli Lilly and Company, Astellas Pharma Inc., Bausch Health Companies Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc., Salix Pharmaceuticals Ltd., Allergan plc, Synergy Pharmaceuticals Inc.

North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the irritable bowel syndrome (ibs) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the irritable bowel syndrome treatment market by increasing the cost of imported active pharmaceutical ingredients and finished drugs, particularly affecting branded therapies and advanced formulations. The impact is more pronounced across drug manufacturing segments such as lubiprostone, linaclotide, and rifaximin, with asia-pacific and north america being the most affected regions due to their reliance on cross-border pharmaceutical supply chains. However, tariffs have also encouraged local manufacturing, supplier diversification, and increased investments in domestic drug production, supporting long-term supply stability and cost optimization in the market.

The irritable bowel syndrome (ibs) treatment market research report is one of a series of new reports that provides irritable bowel syndrome (ibs) treatment market statistics, including irritable bowel syndrome (ibs) treatment industry global market size, regional shares, competitors with a irritable bowel syndrome (ibs) treatment market share, detailed irritable bowel syndrome (ibs) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the irritable bowel syndrome (ibs) treatment industry. This irritable bowel syndrome (ibs) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Irritable bowel syndrome (IBS) treatment encompasses the different approaches and interventions aimed at managing disorders of the gastrointestinal tract, which are common conditions affecting the stomach and intestines. It is used to relieve constipation, diarrhea, and abdominal discomfort, reduce the frequency and severity of flare-ups, and improve overall quality of life.

The primary drugs used for irritable bowel syndrome (IBS) treatment include lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. Lubiprostone is a medication employed in the management of irritable bowel syndrome (IBS) and acts as a selective chloride channel activator that helps increase fluid secretion in the intestines. Its indications include IBS with constipation, IBS with diarrhea, and IBS with alternating constipation and diarrhea. These medications are distributed through various channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, to different end-users, including hospitals, clinics, and home care settings.

The irritable bowel syndrome (IBS) treatment market includes revenues earned by entities by providing services such as consultation, cognitive-behavioral therapy (CBT), hypnotherapy, psychological therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The irritable bowel syndrome (IBS) market also includes sales of antispasmodics, fiber supplements, laxatives, probiotics, and certain medications targeting gut function. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.